Trial Profile
Therapeutic efficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD) in impaired glucose tolerance (IGT): a pilot study.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Oct 2014
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Glucose intolerance
- Focus Pharmacodynamics
- 28 Oct 2014 Status changed from not yet recruiting to discontinued as reported by University Hospital Medical Information Network - Japan
- 05 Sep 2011 New trial record